Skip to main content
main-content

Spondyloarthropathies

Feature content

07-02-2020 | Spondyloarthropathies | Editorial | Article

The microbiome in spondyloarthritis and its relationship with the IL-23/IL-17 axis

Tejpal Gill discusses the relationship between the microbiome and the IL-23/IL-17 axis in spondyloarthritis.

08-01-2020 | Psoriatic arthritis | Feature | Article

​​​​​​​At a glance: Phase 3 trials of IL-17A inhibitors in PsA

A quick-reference guide to the phase 3 trials of the IL-17A inhibitors secukinumab and ixekizumab in patients with psoriatic arthritis.

01-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

Researcher comment: The DISCOVER-2 trial

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).

01-11-2019 | Psoriatic arthritis | Podcast | Article

Discussing the guidelines for managing psoriatic arthritis: Part 2

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

18-10-2019 | Psoriatic arthritis | Podcast | Article

Discussing the guidelines for managing psoriatic arthritis: Part 1

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.

11-10-2019 | Axial spondyloarthritis | Editorial | Article

Do current therapies slow radiographic progression in axial spondyloarthritis/ ankylosing spondylitis?

Preston Le, Stephanie Qi, and Liron Caplan discuss the efficacy of current therapies in slowing radiographic progression of ankylosing spondylitis.

13-09-2019 | Axial spondyloarthritis | Feature | Article

A closer look at the US guidelines for managing axSpA

Michael Ward talks about what’s new in the updated US guidelines for the management of ankylosing spondylitis and nonradiographic axial spondyloarthritis.

13-09-2019 | Ankylosing spondylitis | Feature | Article

At a glance: Phase 3 trials of IL-17A inhibitors in ankylosing spondylitis

A quick-reference guide to the phase 3 trials of IL-17A inhibitors for the treatment of ankylosing spondylitis.

21-08-2019 | Tofacitinib | Feature | Article

Tofacitinib black box warning: A cause for concern?

Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.

23-07-2019 | Axial spondyloarthritis | Feature | Article

Into the clinic: Certolizumab pegol for nonradiographic axSpA

medwireNews talks to Walter Maksymowych and Marina Magrey about the impact of the recent FDA approval of certolizumab pegol for nonradiographic axial spondyloarthritis, and why the approval happened so much later in the USA than in Europe.

10-07-2019 | Psoriatic arthritis | Highlight | Article

Methotrexate versus etanercept as first-line therapy for psoriatic arthritis

William Tillett, Deepak Jadon, and Jobie Evans debate the clinical reasons relating to the efficacy, safety, and practicality of using etanercept or methotrexate as first-line therapy for psoriatic arthritis.

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: The SPIRIT-H2H trial

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis (7:15).

12-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: Tildrakizumab shows promise for PsA

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

10-06-2019 | Psoriatic arthritis | Feature | Article

A closer look at guidelines for the management of PsA

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up

medwireNews rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

19-12-2018 | Diagnosis and screening | Podcast | Video

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

18-12-2018 | Psoriatic arthritis | Feature | Article

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Image Credits